Abstract: Provided are an improved process for preparing a dimethyl-2,3-dihydro-1H-indene derivative of Formula 1 or a pharmaceutically acceptable salt thereof, and intermediates useful for the process, where the process for preparing a compound of Formula 1 or its stereoisomer via the intermediate(s) allows to minimize the amount of heavy metal (Pd) remaining in the final product, i.e., the compound of Formula 1 or its stereoisomer, and to prepare a stereoisomer of the compound of Formula 1 or a pharmaceutically acceptable salt thereof in high optical purity.

Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additionally, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additionally, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides intermediates useful for the synthesis of an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors; and processes for preparing the same. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. Additional, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides intermediates useful for the synthesis of an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors; and processes for preparing the same. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides a novel process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides a novel process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides an improved process for preparing an aminopyrimidine derivative or pharmaceutically acceptable salt thereof having a selective inhibitory activity against protein kinases, especially against the protein kinases for mutant epidermal growth factor receptors. And also, the present invention provides novel intermediates useful for said process and processes for preparing the same.

Abstract: The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvastatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R2—N—O—R1 moiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof.

Abstract: The present invention provides an improved process for preparing HMG-CoA reductase inhibitors such as rosuvastatin calcium, fluvastatin sodium, and pitavastatin calcium under a mild condition, using a novel amide-bond-containing compound having R2—N—O—R1 moiety as a key intermediate. And also, the present invention provides the novel compound, an intermediate useful for the preparation thereof, and a process for the preparation thereof.

Abstract: This invention relates to a resin composition having high impact strength at low temperatures, comprising a polyamide, a graft copolymer obtained by graft polymerizing a monomer mixture of an aromatic vinyl monomer and a vinyl cyanide monomer to a conjugated diene rubber, a copolymer comprising an aromatic vinyl monomer, a vinyl cyanide monomer and other vinyl monomer copolymerizable with the aromatic vinyl monomer and the vinyl cyanide monomer, a modified hydrogenated block copolymer comprising a conjugated diene rubber and styrene or its derivatives to which has been grafted an unsaturated carboxylic acid or an unsaturated carboxylic anhydride, a copolymer comprising an aromatic vinyl monomer, a maleimide monomer, an unsaturated carboxylic acid or an unsaturated carboxylic anhydride, and other vinyl monomer copolymerizable with the aromatic vinyl monomer, and a graft copolymer obtained by graft polymerizing a maleic anhydride to an ethylene-propylene rubber.

Abstract: The present invention relates to resin compositions having a good compatibility of polyphenylene ether and polyamide and a natural color, which comprise (A) 5 to 95 parts by weight of a polyphenylene ether, (B) 1 to 50 parts by weight of a functionalized aromatic vinyl graft copolymer which is prepared by melt blending 100 parts by weight of a copolymer which is prepared by graft polymerizing 20 to 99 parts by weight of aromatic vinyl monomers onto 1 to 80 parts by weight of synthetic rubber polymer, 0.01 to 2 parts by weight of an organic peroxide and 0.01 to 10 parts by weight of reactive monomers having an unsaturated carboxylic acid or anhydride group, and (C) 5 to 95 parts by weight of a polyamide and optionally (D) up to 40 parts by weight of a synthetic resinous impact modifier.